Back to News

Massachusetts Institute of Technology (MIT)

MIT licenses patent rights relevant to GS030, supporting GenSight Biologics’ optogenetics platform and its ambition to restore vision through novel mechanisms.

Back to News

A New Chapter

Founded in 2012 to realize the potential of gene therapy, GenSight Biologics has grown into a clinical-stage company advancing multiple programs. In 2024, under a new management team, the company entered a new phase and is now accelerating its clinical and regulatory activities.

Explore investors’ hub

GenSight Biologics S.A.
74 rue du Faubourg Saint-Antoine
75012 Paris
France